evipedia.ai
← Back

Syringic Acid for Health & Longevity

Created on 11/01/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Syringic acid is a plant compound found in olives, dates, red grapes and walnuts, studied as a possible supplement for blood sugar control and the aging brain. Animal studies report broad benefits, but none has been tested with oral syringic acid in people; the few human signals are indirect and small. No human harm has been reported, yet no long-term safety study or established human dose exists. (Full Review)

Protocol

Food-based approach
Olives, dates, red grapes, walnuts
Plant-rich diets supply syringic acid without supplementation
Animal-derived dose range
About 280–1,100 mg/day
Rat 25–100 mg/kg/day converted by body surface area at 70 kg; untested in humans
Single or split doses
Two or three doses daily
Common practice, given the short rodent half-life (about 2 hours)
Time to effect
Glycemic control
6 months
Measured with a multi-compound extract; oral syringic acid has no human time-course data
Topical cosmetic use
4–12 weeks
Cosmetic trial assessed skin at 4, 8 and 12 weeks; results not yet posted

Benefits

Contraindications
  • Pregnancy and breastfeeding
  • Hyperthyroidism or TSH below the laboratory reference range
  • Diabetes treated with insulin or sulfonylureas with prior hypoglycemia
  • Advanced kidney disease
    •
Key Interactions
Theoretical (inferred from mechanism)
  • Glucose-lowering drugs (metformin, insulin)
  • Antihypertensives (amlodipine, lisinopril)
  • Thyroid drugs (levothyroxine)
  • OAT3 substrates (methotrexate, ibuprofen)
  • Glucose- or blood-pressure-lowering supplements (berberine, cinnamon extract)
  • Other phenolic-acid supplements (gallic acid, ferulic acid)
  • Very-low-carbohydrate diets or prolonged fasting
    •

Risk & Side Effects

  • High:
  • Medium:
  • Low:
  • Speculative: Thyroid hormone stimulation, high-dose liver & kidney changes, excess glucose lowering with diabetes drugs
    •

Monitoring

Marker Target Why
Fasting glucose 65–99 mg/dL Expected to change; hypoglycemia safety check
HbA1c 4.0–5.6% Expected to change
Blood pressure Below 120/80 mmHg Expected to change; hypotension safety check
TSH 0.4–4.0 mIU/L Safety check; a fall below range stops use
ALT 7–56 U/L Liver injury safety check
Creatinine 0.6–1.3 mg/dL Kidney safety check

Cadence: Baseline panel, repeat at 6–8 weeks, then every 3–6 months while use continues; weekly home glucose and blood-pressure checks during the first month for anyone on related drugs

Qualitative Assessment

  • Skin appearance for topical use: lesion counts, redness and wrinkle depth in monthly photographs
  • Energy and alertness after meals
  • Dizziness on standing, a hypotension signal
  • Palpitations, heat intolerance or tremor, signals of thyroid over-stimulation
  • Self-rated memory and mental clarity
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.